Table 1.
Naive MSCs transplantation in IBD animal models
| Diseases | Source | Model | Results | Refs. |
|---|---|---|---|---|
| TNBS-induced colitis | UC | BALB/c mice | Reducing colitis by suppression of the Th1/17 activation | [227] |
| DSS-induced colitis | BM | C57BL/6 mice | Reducing the numbers of neutrophils in colon tissue and metalloproteinase activity in the mucosa while promoting the Tregs population | [85] |
| DSS-induced colitis | BM | BALB/c mice | Attenuation of TNF-α and IL-1β levels in both the inflamed colon and serum | [68] |
| DSS and TNBS-induced colitis | UC | BALB/c mice | Amelioration of colitis by up-regulating NOD2/COX2 signaling pathways | [69] |
| TNBS-induced colitis | Placenta | BALB/c mice | Promoting the therapeutic potential of MSCs by improving the PGE2-mediated M2 macrophage polarization by combination therapy with chitosan-based hydrogel | [228] |
| TNBS-induced colitis |
AT BM |
Wistar rats | Promoting VEGF and TGF-β levels while attenuating TNF-α and IL-1β | [229] |
| TNBS-induced colitis | BM | Wistar rats | MSCs’ partial differentiation into IECs and secreting VEGF and TGF-β1 | [230] |
| DSS-induced colitis | BM | C57BL/6 mice | Recruiting M2 macrophage to reduce colitis severity by secretion of the TGFβ1 | [231] |
| AOM and DSS-induced colitis | UC | C57BL/6 mice | Enhancing Treg cells differentiation by MSCs-secreted TGF-β | [232] |
| DSS-induced colitis | AT | C57BL/6 mice | Stimulation of the polarization of the M2 macrophages by MScs-secreted TSG-6 | [233] |
| DSS-induced colitis | BM | C57BL/6 mice | Suppression of dendritic cells (DCs) activation by the release of galectin 3 | [58] |
| AOM and DSS-induced colitis | BM | C57BL/6 mice | Amelioration of histological damage along with reducing TNF-α, IL-1β, and IL-6 levels and down-regulation of STAT3 phosphorylation in colon tissue | [234] |
| DSS-induced colitis | UC | C57BL/6 mice | Eliciting anti-inflammatory response in colon tissue by improving Treg/Th17 cells ratio in the spleen and mesenteric lymph nodes | [235] |
| DSS-induced colitis | BM | C57BL/6 mice | Improved levels of IDO and IL-10 in serum | [236] |
| DSS-induced colitis | BM | C57BL/6 mice | Improving IL-10 levels, the inflamed colons | [237] |
| DSS-induced colitis | BM | BALB/c mice | Potentiating intestinal integrity by up-regulation of E-cadherin expression | [25] |
| DSS-induced colitis | UCB | C57BL/6 mice | Reducing T cell infiltration into the inflamed colon while promoting Tregs frequency | [114] |
| DSS-induced colitis | UC | C57BL/6 mice | Attenuation of disease activity index (DAI), histological colitis scores along with promoting body weight | [22] |
| DSS-induced colitis | BM | C57BL/6 mice | Induction of DCs differentiation into rDCs, leading to ameliorated chronic colitis | [71] |
| TNBS-induced colitis | BM | Hartley guinea pigs | Diminishment of the immune cell infiltration to damaged colons and also reducing neuronal loss in colon tissue | [238] |
| TNBS-induced colitis |
AT BM |
Hartley guinea pigs | Amelioration of enteric neuropathy and plexitis | [239] |
| DSS-induced colitis | BM | C57BL/6 mice | Improvement of the MSCs therapeutic effects by human cord blood-derived platelet lysate | [126] |
| DSS-induced colitis | UC | C57BL/6 mice | Amelioration of colon and liver pathology by attenuating the LPS levels and TNF-α, IFN-γ, IL-1β, IL-17A, TLR4, TRAF6, and NF-κB expression in inflamed colon | [240] |
| TNBS-induced colitis | AT | C57BL/6 mice | Reducing colitis severity and diarrhea and enhancing body weight and survival | [241] |
| DSS-induced colitis | AM | SD rats | Reducing DAI score, weight loss, colon shortening, and the histological colitis score in association with down-regulation of TNF-α, IL-1β, and MIP | [242] |
| TNBS-induced colitis | AT | Hartley guinea pigs | Attenuation of weight loss, colonic tissue damage, and immune cell infiltration | [243] |
| DSS-induced colitis | AT | C57BL/6 mice | Enhancing Tregs by MSCs-secreted PGE2 | [79] |
| TNBS-induced colitis | BM | SD rats | Enhancing MSCs recruitment to the colonic mucosa by combination therapy with G-CSF leads to reduced DAI, MPO activity | [125] |
| TNBS-induced colitis | UC | BALB/c mice | Improvement of CD5 + B cells and Tregs while decreasing Th1 cells, Th17 cells, and various pro-inflammatory cytokines levels in inflamed colon | [116] |
| DSS-induced colitis | BM | C57BL/6 mice | Improvement of IL-10 secretion by MSCs upon combination therapy with wogonin | [128] |
| TNBS-induced colitis | BM | C57BL/6 mice | Exerting gastrointestinal mucosal tissues repair by MSCs-secreted IGFBP7 | [244] |
MSCs mesenchymal stem/stromal cells, BM bone marrow, UC umbilical cord, UCB umbilical cord blood, AT adipose tissue, TNBS 2,4,6-trinitrobenzene sulfonic acid, DSS dextran sulfate sodium, AOM azoxymethane, Th T helper 1/2/17, FOXP3 Forkhead box P3, IL-1 interleukin-1β, TNF-α Tumor necrosis factor-alpha, NOD2 nucleotide-binding oligomerization domain-containing protein 2, COX-2 cyclooxygenase-2, TGF-β transforming growth factor-beta, PGE2 prostaglandin E2, VEGF vascular endothelial growth factor, Tregs regulatory T cells, TSG-6 TNF-stimulated gene 6, STAT3 signal transducer and activator of transcription 3, IDO indoleamine 2,3-dioxygenase, IFN-γ interferon-gamma, IL interleukin, rDCs regulatory dendritic cells, TLRs toll-like receptors, TRAF6 tumor necrosis factor receptor-associated factor 6, NF-κB nuclear factor kappa B, NLRP3 NLR family pyrin domain containing 3, G-CSF granulocyte colony-stimulating factor, MPO myeloperoxidase, IGFBP7 insulin-like growth factor-binding protein 7, MIF migration inhibitory factor